First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB

Eur Respir J. 2016 May;47(5):1581-4. doi: 10.1183/13993003.01980-2015. Epub 2016 Feb 25.

Abstract

The first successful use of bedaquiline for 18 months for XDR-TB as part of an optimised background regimen http://ow.ly/XE34x

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Diarylquinolines / administration & dosage*
  • Diarylquinolines / adverse effects
  • Diarylquinolines / therapeutic use
  • Drug Administration Schedule
  • Female
  • Humans
  • Safety
  • Tuberculosis, Multidrug-Resistant / drug therapy*
  • Young Adult

Substances

  • Diarylquinolines
  • bedaquiline